40-O-(2-hydroxyethyl)-rapamycin is available under the name everolimus. In the procedure of invalidation, the petitioner ...

"At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and enhanced tumor suppression with both everolimus and capivasertib. OP-3136, our potent ...

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will attend the 2024 Child Neurology Society (CNS) ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

Abbott announces positive data from LIFE-BTK trial of Esprit BTK System in people with peripheral artery disease below the knee: Las Vegas Wednesday, November 6, 2024, 14:00 Hrs [ ...

The LIFE-BTK trial evaluated Esprit BTK in 260 people worldwide with PAD below the knee. Abbott’s stent is an everolimus-eluting resorbable scaffold system that treats lesions via vessel recoil and ...

The Espirit everolimus-eluting scaffold. [Image from the Abbott website] Abbott (NYSE:ABT) today announced data demonstrating ...

The Esprit everolimus-eluting scaffold. [Image from the Abbott website] Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

TCT 15: Impact of High Lipoprotein(a) Levels on 5-Year Clinical Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent in Korean Population Receive the the latest news, research ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...